- Home
- APLS
as 11-21-2024 3:30pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.4B | IPO Year: | 2017 |
| Target Price: | $51.00 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.34 - $73.80 | Next Earning Date: | 11-05-2024 |
| Revenue: | $715,216,000 | Revenue Growth: | 162.10% |
| Revenue Growth (this year): | 95.59% | Revenue Growth (next year): | 13.77% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | APLS | Director | Sep 16 '24 | Sell | $36.44 | 37,000 | $1,340,596.80 | 107,524 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Sep 16 '24 | Sell | $36.21 | 192 | $6,951.55 | 38,141 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Sep 3 '24 | Sell | $39.49 | 550 | $21,720.05 | 38,141 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
TipRanks
14 days ago
Apellis price target lowered to $30 from $43 at Wells Fargo
TipRanks
14 days ago
Apellis price target lowered to $47 from $61 at BofA
Zacks
15 days ago
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
MT Newswires
15 days ago
RBC Capital Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Maintains Sector Perform Rating
MT Newswires
15 days ago
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating
GuruFocus.com
16 days ago
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
Motley Fool
16 days ago
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.